Tandem Gross Profit vs Net Income From Continuing Ops Analysis
TNDM Stock | USD 51.39 2.07 4.20% |
Tandem Diabetes financial indicator trend analysis is much more than just breaking down Tandem Diabetes Care prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tandem Diabetes Care is a good investment. Please check the relationship between Tandem Diabetes Gross Profit and its Net Income From Continuing Ops accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Gross Profit vs Net Income From Continuing Ops
Gross Profit vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tandem Diabetes Care Gross Profit account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Tandem Diabetes' Gross Profit and Net Income From Continuing Ops is -0.25. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Tandem Diabetes Care, assuming nothing else is changed. The correlation between historical values of Tandem Diabetes' Gross Profit and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Tandem Diabetes Care are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Gross Profit i.e., Tandem Diabetes' Gross Profit and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | -0.25 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Tandem Diabetes Care minus its cost of goods sold. It is profit before Tandem Diabetes operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Net Income From Continuing Ops
Most indicators from Tandem Diabetes' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Selling General Administrative is very stable compared to the past year. As of the 23rd of May 2024, Tax Provision is likely to grow to about 2.5 M, while Enterprise Value Over EBITDA is likely to drop (20.24).
2021 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 7.6M | 5.8M | Depreciation And Amortization | 13.8M | 15.7M | 9.4M |
Tandem Diabetes fundamental ratios Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Other Current Liab | 71.5M | 70.5M | 84.4M | 77.6M | 84.6M | 88.8M | |
Total Current Liabilities | 99.4M | 103.9M | 131.9M | 165.3M | 195.3M | 205.0M | |
Total Stockholder Equity | 195.0M | 366.3M | 433.1M | 439.9M | 313.6M | 160.8M | |
Other Liab | 17.7M | 27.4M | 34.8M | 36.1M | 41.5M | 43.6M | |
Property Plant And Equipment Net | 48.5M | 69.8M | 77.9M | 179.2M | 164.3M | 172.5M | |
Net Debt | (30.8M) | 133.7M | 243.5M | 247.4M | 356.8M | 374.6M | |
Retained Earnings | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (951.8M) | (904.2M) | |
Accounts Payable | 17.7M | 17.8M | 28.0M | 55.7M | 49.6M | 52.1M | |
Cash | 51.2M | 94.6M | 71.2M | 172.5M | 58.9M | 65.4M | |
Non Current Assets Total | 50.0M | 79.2M | 93.6M | 202.8M | 204.7M | 214.9M | |
Non Currrent Assets Other | 708K | 580K | 9.1M | 19.0M | 37.6M | 39.4M | |
Other Assets | 708K | 29.2M | 9.1M | 10.7M | 12.3M | 12.9M | |
Cash And Short Term Investments | 176.5M | 484.9M | 623.8M | 616.9M | 467.9M | 242.0M | |
Net Receivables | 46.6M | 82.2M | 110.7M | 114.7M | 105.6M | 110.8M | |
Common Stock Total Equity | 59K | 14.3M | 64K | 65K | 74.8K | 71.0K | |
Common Stock Shares Outstanding | 58.5M | 61.0M | 64.3M | 64.1M | 65.0M | 68.2M | |
Short Term Investments | 125.3M | 390.3M | 552.6M | 444.4M | 409.0M | 429.5M | |
Liabilities And Stockholders Equity | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Non Current Liabilities Total | 31.7M | 246.3M | 340.2M | 447.5M | 443.8M | 466.0M | |
Inventory | 49.1M | 63.7M | 68.6M | 111.1M | 157.9M | 165.8M | |
Other Current Assets | 4.0M | 6.4M | 8.4M | 7.2M | 16.6M | 17.4M | |
Other Stockholder Equity | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 669.8M | |
Total Liab | 131.1M | 350.1M | 472.0M | 612.8M | 639.0M | 671.0M | |
Property Plant And Equipment Gross | 48.5M | 50.0M | 77.9M | 179.2M | 217.1M | 228.0M | |
Total Current Assets | 276.1M | 637.2M | 811.5M | 850.0M | 748.0M | 785.4M | |
Accumulated Other Comprehensive Income | 122K | 220K | (616K) | (1.8M) | 1.4M | 1.4M | |
Common Stock | 59K | 62K | 64K | 65K | 66K | 41.6K | |
Property Plant Equipment | 32.9M | 50.0M | 50.4M | 68.6M | 78.8M | 82.8M | |
Current Deferred Revenue | 3.9M | 6.1M | 10.2M | 18.8M | 44.0M | 46.2M | |
Intangible Assets | 777K | 8.8M | 6.6M | 4.6M | 2.8M | 3.5M | |
Net Tangible Assets | 195.0M | 366.3M | 433.1M | 439.9M | 505.9M | 531.2M | |
Retained Earnings Total Equity | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (656.3M) | (689.1M) | |
Capital Surpluse | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 776.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tandem Diabetes Care using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (2.16) | Revenue Per Share 11.817 | Quarterly Revenue Growth 0.132 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.